May 29, 2025 a 08:38 pm
AMGN: Analysts Ratings - Amgen Inc.
Amgen Inc., a global biotechnology leader, has shown a robust and stable market position through its diverse therapeutic products and strategic partnerships. The stock continues to attract interest, evident from the steady number of analyst ratings and a slight increase in "Strong Buy" recommendations in recent months. Investors and analysts are cautiously optimistic about Amgen's growth potential, driven by its diverse portfolio and ongoing R&D collaborations.
Historical Stock Grades
| Rating Type | Number of Ratings | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 10 | |
| Hold | 15 | |
| Sell | 2 | |
| Strong Sell | 1 |
Sentiment Development
Over the recent months, Amgen Inc. has seen a consistent sentiment among analysts, with a moderate number of "Hold" ratings dominating the scene. The number of "Strong Buy" ratings has slightly increased, indicating a growing confidence in the stock's potential.
- The total number of ratings has slightly fluctuated, reflecting varying market conditions and company performance insights.
- Increase in "Strong Buy" ratings might indicate a strengthening belief in Amgen's strategic direction and R&D prospects.
- The "Hold" category consistently remains the most frequent, suggesting a wait-and-see approach among analysts.
Percentage Trends
Analyzing the data, there is a noticeable trend towards more conservative recommendations such as "Hold," which could highlight market caution or uncertainty. However, the modest rise in "Strong Buy" ratings hints at a possible bullish shift.
- The distribution of ratings in the past month shows: 15% Strong Buy, 25% Buy, 37.5% Hold, 5% Sell, 2.5% Strong Sell.
- The "Strong Buy" category has marginally increased, while "Hold" ratings have maintained stability.
- This suggests a cautious optimism, with analysts watching for potential enhancing factors in Amgen's business execution.
- Over the last year, the most noticeable shift has been from "Buy" to "Hold," reflecting a conservative market sentiment.
Latest Analyst Recommendations
Recent analyst recommendations for Amgen Inc. show a stable outlook, with many firms maintaining their previous ratings. This stability reflects a steady confidence in Amgen's future performance.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-16 | Overweight | Overweight | Piper Sandler |
| 2025-05-07 | Neutral | Neutral | Mizuho |
| 2025-05-02 | Outperform | Outperform | RBC Capital |
| 2025-05-02 | Neutral | Neutral | UBS |
| 2025-04-14 | Neutral | Neutral | UBS |
Analyst Recommendations with Change of Opinion
The recommendations reflect significant changes in opinion over the past year, with both downgrades and upgrades highlighting shifts in market perception regarding Amgen's performance and potential.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-10-14 | Hold | Buy | Truist Securities |
| 2024-08-07 | Equal Weight | Overweight | Wells Fargo |
| 2024-05-03 | Outperform | Market Perform | William Blair |
| 2024-05-03 | Equal Weight | Underweight | Barclays |
| 2023-12-21 | Buy | Neutral | Daiwa Capital |
Interpretation
Amgen's current market perception showcases a landscape of cautious optimism with inclinations towards a potential growth trajectory. Despite the stable recommendation trends, subtle shifts towards "Strong Buy" ratings hint at a changing outlook among analysts. Yet, the predominance of "Hold" suggests a balanced stance, reflecting an anticipation of further evidence of growth before commitment to more aggressive buy recommendations. The consistency in recommendations over time underscores a relative stability in analysts' market perception.
Conclusion
The overall sentiment for Amgen Inc. remains cautiously optimistic, with analysts reflecting stability in recommendations. Though uncertainties persist, the presence of collaborations and a diverse product line pave the way for growth opportunities. Amgen's strategic focus and R&D efforts continue to be decisive factors endorsed by analysts. Weigh carefully the risks and potential for gains, considering Amgen's persistent presence and adaptability in the biotechnology sector. Its proven track record suggests resilience, yet industry competition remains a standing challenge.